PharmaMar has published the results of its antibody conjugate active in breast, ovarian and gastric cancers that express HER2

- The antibody conjugates MI130004 is the result of combining trastuzumab with the molecule of marine origin belonging to PharmaMar, PM050489

- The prestigious magazine Molecular Cancer Therapeutics, from the American Association for Cancer Research (AACR), has published the results of this antibody conjugate (http://mct.aacrjournals.org/content/early/2018/02/13/1535-7163.MCT-17-0795)

- This new molecule causes in HER expressed breast, ovarian and gastric cancers, a longer lasting response and also inhibiting tumor growth increasing the progression free survival in comparison with trastuzumab

**Madrid, 16th February, 2018.** PharmaMar (MSE:PHM) has announced the positive results of MI130004, a novel antibody conjugate combining trastuzumab with PM050489, a molecule of marine origin. The company has analyzed its antitumor activity in different tumor cell lines (breast, ovarian and gastric cancers) that express different levels of HER2 in both in vitro and in vivo tests.

The results published by the prestigious magazine Molecular Cancer Therapeutics, from the American Association for Cancer Research (AACR), (http://mct.aacrjournals.org/content/early/2018/02/13/1535-7163.MCT-17-0795) show that this new molecule provokes in tumors that express HER2 a longer lasting response and inhibits significantly tumor growth providing a higher median progression free survival time in comparison with trastuzumab.

MI130004 is the result of the research carried out by PharmaMar to identify and synthesize molecules of a marine origin for their use as active agents in antibody-drug conjugates, as is the case with PM050489.
As a Company, PharmaMar is positioning itself as a supplier of cytotoxic products that are necessary for companies specialized in the antibody-drug conjugate technology.

**About PharmaMar**
Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has other clinical-stage programs under development for several types of solid and hematological cancers, Zepsyre® (PM1183), plitidepsin, PM184 and PM14. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium, Austria and the United States. PharmaMar fully owns other companies: GENOMICA, a leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at [www.pharmamar.com](http://www.pharmamar.com).

**Disclaimer**
This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

**Media Contact:**
Alfonso Ortín – Communications Director [aortin@pharmamar.com](mailto:aortin@pharmamar.com) Mobile: +34609493127
Paula Fernández – Media Relations Manager [pfalarcon@pharmamar.com](mailto:pfalarcon@pharmamar.com) Mobile: +34 638796215
Phone: +34 918466000

**Investor Relations:**
Phone: +34 914444500

Or please visit our website at [www.pharmamar.com](http://www.pharmamar.com)
**ANTIBODIES**

- **Variable region**
- **Linker**
- **Constant region**
- **Active compound**

**CANCER CELL**

- **The antibodies bind to the cancer cell**
- **Once inside they begin to break up**
- **Liberating the active compound and killing the cancer cell**